China

Trump tariffs threaten to cost medical device industry billions
Trump tariffs threaten to cost medical device industry billions
Fierce Biotech
devices
Donald Trump
China
tariffs
Flag link:
Novartis, still embroiled in Greek probe, faces kickback allegation in China—again
Novartis, still embroiled in Greek probe, faces kickback allegation in China—again
Fierce Pharma
Novartis
China
Greece
kickbacks
bribery
Flag link:
Trump Tariffs Target Key Ingredients for Dozens of Drugs
Trump Tariffs Target Key Ingredients for Dozens of Drugs
Bloomberg
Donald Trump
China
tariffs
drug pricing
Flag link:
After a makeover and hiring spree, China’s drug agency is romping and stomping on new reviews and approvals
After a makeover and hiring spree, China’s drug agency is romping and stomping on new reviews and approvals
Endpoints
China
CFDA
Flag link:
Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize DNA Immunotherapy product (VGX-3100) in Greater China
Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize DNA Immunotherapy product (VGX-3100) in Greater China
CP Wire
Inovio
China
ApolloBio
VGX-3100
DNAi-based therapeutics
HPV
Flag link:
China's Aim to Remove Cancer Drug Taxes May Boost Pfizer, Glaxo
China's Aim to Remove Cancer Drug Taxes May Boost Pfizer, Glaxo
Bloomberg
China
Pfizer
GSK
cancer
taxes
Flag link:
2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?
2 Biotech Stocks Near All-Time Highs: Can They Keep Climbing?
Motley Fool
biotech
BeiGene
China
Celgene
AnaptysBio
ANB020
eczema
Flag link:
Bye CFDA: China’s drug regulator to take new shape in major government restructuring
Bye CFDA: China’s drug regulator to take new shape in major government restructuring
Endpoints
China
regulatory
CFDA
Flag link:
North of a billion biotech VC dollars to come from C-Bridge, Rothschild as global biopharma capital flows
North of a billion biotech VC dollars to come from C-Bridge, Rothschild as global biopharma capital flows
Endpoints
venture capital
biotech
C-Bridge
Rothschild
China
Europe
Flag link:
AstraZeneca pins its hopes on China
AstraZeneca pins its hopes on China
Biopharma Dive
China
AstraZeneca
earnings
Flag link:
Chinese drugmakers tap GE tech, seeing biologic boom ahead
Chinese drugmakers tap GE tech, seeing biologic boom ahead
Biopharma Dive
China
biologics
GE Healthcare
Clover BioPharmaceuticals
Flag link:
Consortium of Chinese companies tries to acquire J&J’s LifeScan and Calibra Medical ($3-4bn)
Consortium of Chinese companies tries to acquire J&J’s LifeScan and Calibra Medical ($3-4bn)
GoinPharma
China
JNJ
LifeScan
Calibra
M&A
Flag link:
Closing JPM18: Winners and losers, brighter days for neuroscience
Closing JPM18: Winners and losers, brighter days for neuroscience
Biopharma Dive
JPMHC 2018
Neurosciences
China
Sanofi
tax reform
GSK
Biogen
Celgene
channel stuffing
Flag link:
Indian, Chinese drugmakers eye Sanofi's European generics unit for $2B deal: report
Indian, Chinese drugmakers eye Sanofi's European generics unit for $2B deal: report
Fierce Pharma
Sanofi
Europe
generics
China
India
Flag link:
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Fierce Pharma
China
Opdivo
Repatha
Lynparza
drug approvals
Bristol-Myers Squibb
Amgen
AstraZeneca
Eli Lilly
Gilead Sciences
Flag link:
Star drugs like BMS’ Opdivo, AstraZeneca’s Lynparza will get speedy OKs in China this year, new report predicts
Star drugs like BMS’ Opdivo, AstraZeneca’s Lynparza will get speedy OKs in China this year, new report predicts
Endpoints
Bristol-Myers Squibb
AstraZeneca
Opdivo
Lynparza
China
Flag link:
J&J wows with a $350M cash deal to partner on CAR-T with Legend, a one-time unknown until its star turn at ASCO
J&J wows with a $350M cash deal to partner on CAR-T with Legend, a one-time unknown until its star turn at ASCO
Endpoints
JNJ
CAR-T
Legend Biotech
LCAR-B38M
BCMA
China
Flag link:
Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success
Bristol-Myers' Opdivo's Lung Cancer Study Meets Early Success
Yahoo/Zacks.com
Bristol-Myers Squibb
Opdivo
clinical trials
Docetaxel
China
Flag link:
Bristol-Myers set to get a boost in China as Opdivo aces PhIII lung cancer study early
Bristol-Myers set to get a boost in China as Opdivo aces PhIII lung cancer study early
Endpoints
Bristol-Myers Squibb
Opdivo
China
Docetaxel
lung cancer
Flag link:
Gilead prices hepatitis C giant Sovaldi in China at one-fifth the U.S. price: report
Gilead prices hepatitis C giant Sovaldi in China at one-fifth the U.S. price: report
Fierce Pharma
Gilead Sciences
hepatitis C
Sovaldi
China
drug pricing
Flag link:

Pages